OxyHelp

Overview

OxyHelp is a Romania-based manufacturer of hard-shell hyperbaric chambers founded in 2017 and sold primarily into the European market. Its product line — from the OxyLife I monoplace at 1.5 ATA through to the OxyLife 2ATA model reaching 2.0 ATA, and multiplace units seating two to five people — occupies a structural gap that exists in the consumer-to-clinic spectrum: above the thin-walled Chinese hard-shell tier on one end, and meaningfully below the $100,000+ hospital-grade clinical chambers on the other.

The engineering emphasis is on build material and containment quality: polished stainless-steel construction, pressure-sealed doors fitted with anti-friction bearings, and dual over-pressure safety mechanisms with automatic depressurization. Models are designed to accommodate a stationary bike inside the chamber, enabling aerobic exercise during pressurized sessions — a feature absent from the soft-shell category and uncommon even in this price tier of hard-shell units. CE certification indicates conformance to European product safety standards under the applicable EU regulatory framework.

The foundational caveat for US buyers: OxyHelp does not hold FDA 510(k) clearance for the US market. For EU buyers, CE certification is the relevant regulatory credential. For US buyers, the absence of FDA clearance is a material purchasing consideration that should be weighed explicitly, not assumed away.

Product Line and Specifications

Model	Shell Type	Max Pressure	Capacity	Notable Feature
OxyLife I	Hard-shell monoplace	1.5 ATA	1 person	Entry hard-shell
OxyLife 2ATA	Hard-shell monoplace	2.0 ATA	1 person	Highest home-tier pressure
Multiplace models	Hard-shell	TBC per model	2–5 people	Shared-session capacity

Dimension	Spec
Shell material	Polished stainless steel
Door mechanism	Pressure-sealed with anti-friction bearings
Safety	Dual over-pressure mechanisms; automatic depressurization
Exercise capability	Stationary bike accommodation
Certification	CE certified (EU); not FDA-cleared (US)
Warranty	2 years standard; extendable to 3 years
Lead time	4–6 weeks (made-to-order)
Estimated price range	$10,000–$20,000 (USD equivalent; direct inquiry required)
Manufacturing location	Romania

Hard-Shell Construction: Why It Matters

The hard-shell vs soft-shell distinction is not cosmetic. Soft chambers inflate a textile envelope to 1.3–1.5 ATA; hard-shell chambers with rigid metal walls sustain higher pressure more stably and allow more precise oxygen delivery by mask or hood. The OxyLife 2ATA at 2.0 ATA occupies the lower bound of the pressure range used in most published HBOT clinical literature — wound healing, decompression sickness, CO poisoning — which was largely generated at 2.0–2.5 ATA in hospital hard-shell chambers. Wellness and biohacking use at 2.0 ATA remains off-label; the evidence for those applications is limited. But buyers targeting proximity to clinical-protocol pressure are at least in the right tier.

OxyHelp’s stainless-steel construction and pressure-sealed door with anti-friction bearings are inspectable differentiators from low-cost Chinese hard-shell imports. The dual over-pressure safety system — two independent pathways to pressure release if the primary mechanism fails — is a meaningful engineering feature in a category where over-pressurization is the most serious hardware failure mode.

Regulatory Status & Safety

OxyHelp does not hold FDA 510(k) clearance. For US buyers, this is the central regulatory fact. CE certification — which OxyHelp holds under European product safety frameworks — is not equivalent to FDA clearance. CE marking indicates compliance with applicable EU directives (medical devices, machinery, pressure vessels depending on classification); it does not constitute FDA authorization to market or sell the device as a medical device in the US.

CE certification in plain terms. The CE mark reflects conformity with applicable EU directives — manufacturing standards, safety testing, and product documentation. For EU buyers it is the correct regulatory credential to check. It does not establish efficacy for any specific indication, does not replace FDA clearance for US purchasers, and should not be read as regulatory endorsement of outcome claims in marketing materials.

Indication framing. FDA-cleared HBOT indications — decompression sickness, CO poisoning, non-healing wounds, gas gangrene, and roughly 14 others — were established for clinical chambers at 2.0–2.5 ATA under physician supervision with 100% oxygen delivery. A home OxyHelp unit at 2.0 ATA with an oxygen concentrator is structurally different from that clinical setting. Wellness and biohacking applications are off-label; evidence for those uses at any pressure is limited and should not be extrapolated from the clinical indication literature.

Safety. Consult a physician before using HBOT; contraindications include certain ear and lung conditions, untreated pneumothorax, some medications, and recent ear surgery. Hard-shell chamber operation at 2.0 ATA involves greater pressurization forces than soft-shell 1.3 ATA units, making proper door-sealing procedure, pressure equalization, and operator protocol more consequential. OxyHelp’s dual over-pressure safety mechanism and automatic depressurization address the most serious hardware failure mode; user-side preparation and physician screening address the contraindication risk. Neither substitutes for the other. Oxygen enrichment inside a pressurized enclosure is a fire hazard; all smoking, open flames, and ignition sources must be eliminated from the operating environment.

Where It Fits — And Where It Doesn’t

Buy OxyHelp if:

• EU or CE-market buyer wanting European-manufactured hard-shell with local regulatory coverage
• 2.0 ATA hard-shell capability at $10K–$20K, with not-FDA-cleared status accepted for US personal use
• Premium build quality (stainless steel, pressure-sealed door, dual safety) is a priority over budget pricing
• Multiplace capacity for clinic or spa use in an EU context

Consider alternatives if:

• US buyer requiring FDA clearance — Newtowne (K051759), OxyHealth (K041007), or Summit to Sea (K072757) are FDA-cleared soft-shell options
• Budget under $10,000 — Macy-Pan or OxyRevo hard-shells at roughly half the price, with their own regulatory caveats
• 4–6 week lead time is a problem — OxyHelp is made-to-order
• US-local dealer service is required — OxyHelp’s US network is limited

3-Year Cost of Ownership

Component	Estimated Cost
OxyHelp OxyLife I (1.5 ATA) — estimated	~$10,000–$14,000
OxyHelp OxyLife 2ATA — estimated	~$14,000–$20,000
Medical-grade O₂ concentrator (separate, 10 L/min class)	~$2,500–$4,000
Installation / delivery (heavy unit)	~$500–$1,500
3-year system total (OxyLife 2ATA)	~$17,000–$25,500

Pricing requires direct inquiry; figures are US-dollar estimates based on published range disclosures. Actual pricing confirmed at point of sale.

Compare: Macy-Pan ST-class hard-shell ($5,000–$8,000 + concentrator), Henshaw Hyperbarics UK ($8,000–$25,000 hard-shell), Atlanta Hyperbaric clinical tier ($15,000–$100,000+), OxyHealth Vitaeris 320 soft-shell (~$23,000 US, FDA-cleared).

Verdict

OxyHelp earns a recommended verdict in its target market: EU buyers and clinics wanting a hard-shell chamber at $10,000–$20,000 with CE certification and European manufacturing accountability. The stainless-steel build, pressure-sealed door, dual over-pressure safety, and 2.0 ATA ceiling are real, inspectable differentiators from cheaper Chinese imports. At this price point OxyHelp fills a gap that previously had few options between $3,000 Chinese hard-shells and $100,000 hospital units.

The non-negotiable caveat: OxyHelp does not hold FDA clearance. CE certification does not substitute for 510(k) status in the US. US buyers should treat OxyHelp as a personal-use option acquired with explicit awareness of its regulatory standing — not as a cleared medical device. For US buyers requiring FDA clearance, soft-shell alternatives (Newtowne, OxyHealth, Summit to Sea) remain the only widely available cleared options in the residential market.

Changelog

• 2026-05-07: Initial review published based on OxyHelp published specifications, European manufacturing positioning, and pricing-tier documentation.
• 2026-06-15: Expanded review: full regulatory-status section added, hard-shell vs soft-shell ATA distinction clarified, CE vs FDA clearance distinction made explicit for US buyers, product spec table added, exercise-capability section added, 3-year cost-of-ownership table added, safety note added.